Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure
New England Journal of MedicinePublished 13 November 2020Open access
John R. Teerlink, Rafael Díaz, G. Michael Felker, John J.V. McMurray, Marco Metra, Scott Solomon
Citations618
SJR quartileQ1
SJR score19.08
SNIP13.47
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveWill appear once the snapshot is generated
MethodsWill appear once the snapshot is generated
PopulationWill appear once the snapshot is generated
Sample sizeWill appear once the snapshot is generated
OutcomesWill appear once the snapshot is generated
ResultsWill appear once the snapshot is generated
LimitationsWill appear once the snapshot is generated
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
Among patients with heart failure and a reduced ejection, patients who received omecamtiv mecarbil had a lower incidence of a composite of a heart-failure event or death from cardiovascular causes than those who received placebo.
Abstract
Among patients with heart failure and a reduced ejection, those who received omecamtiv mecarbil had a lower incidence of a composite of a heart-failure event or death from cardiovascular causes than those who received placebo. (Funded by Amgen and others; GALACTIC-HF ClinicalTrials.gov number, NCT02929329; EudraCT number, 2016-002299-28.).
Keywords
Medicine
Journal of the American Statistical AssociationA Proportional Hazards Model for the Subdistribution of a Competing Risk
13,584 Citations1999Jason P. Fine, Malcolm H. Ray
This article proposes methods for combining estimates of the cause-specific hazard functions under the proportional hazards formulation, but these methods do not allow the analyst to directly assess the effect of a covariate on the marginal probability function.
New England Journal of MedicineDapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
6,873 Citations2019John J.V. McMurray, Scott D. Solomon +36 more
New England Journal of MedicineCardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
5,037 Citations2020Milton Packer, Stefan D. Anker +37 more
SGLT2 inhibitors reduce the risk of hospitalization for heart failure in patients regardless of the presence or absence of diabetes, regardless of the presence or absence of diabetes.
Journal of Statistical SoftwareRegularization Paths for Cox's Proportional Hazards Model via Coordinate Descent
2,613 Citations2011Noah Simon, J. Friedman +2 more
This work introduces a pathwise algorithm for the Cox proportional hazards model, regularized by convex combinations of ℓ1 andℓ2 penalties (elastic net), and employs warm starts to find a solution along a regularization path.
British Journal of CancerDesign and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design
2,312 Citations1976Richard Peto, Malcolm C. Pike +8 more
This report is the first simple account yet published for non-statistical physicians of how to analyse efficiently data from clinical trials of survival duration, and it may be preferable to use these statistical methods to study time to local recurrence of tumour, or toStudy time to detectable metastatic spread, in addition to studying total survival.
ScienceCardiac Myosin Activation: A Potential Therapeutic Approach for Systolic Heart Failure
596 Citations2011Fady I. Malik, James J. Hartman +32 more
It is shown that omecamtiv mecarbil binds to the myosin catalytic domain and operates by an allosteric mechanism to increase the transition rate of myOSin into the strongly actin-bound force-generating state.
British Journal of RadiologyRepeated assessment of results in clinical trials of cancer treatment
523 Citations1971J. L. Haybittle
The results of a computer simulation experiment show the extent to which repeated assessment of results before the end of a trial may invalidate the use of the usual significance tests.
Journal of the American College of CardiologyQuantitative Evaluation of Drug or Device Effects on Ventricular Remodeling as Predictors of Therapeutic Effects on Mortality in Patients With Heart Failure and Reduced Ejection Fraction
487 Citations2010Daniel G. Kramer, Thomas A Trikalinos +4 more
In patients with LVD, short-term trial-level therapeutic effects of a drug or device on LV remodeling are associated with longer-term test-level effects on mortality, and the odds for neutral or favorable effects in the mortality RCTs increased with mean increases in LVEF and with mean decreases in EDV and ESV in the remodeling trials.
Statistics in MedicineA graphical approach to sequentially rejective multiple test procedures
417 Citations2008Frank Bretz, Willi Maurer +2 more
A simple iterative graphical approach to construct and perform Bonferroni‐type tests, represented by directed, weighted graphs, where each node corresponds to an elementary hypothesis, together with a simple algorithm to generate such graphs while sequentially testing the individual hypotheses.
The LancetThe effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial
328 Citations2011John G.F. Cleland, John R. Teerlink +19 more
Omecamtiv mecarbil improved cardiac function in patients with heart failure caused by left ventricular dysfunction and could be the first in class of a new therapeutic agent.
Journal of the American College of Cardiology2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials
322 Citations2018Karen A. Hicks, Kenneth W. Mahaffey +62 more
This publication describes uniform definitions for cardiovascular and stroke outcomes developed by the Standardized Data Collection for Cardiovascular Trials Initiative and the U.S. Food and Drug Administration (FDA).
The LancetChronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial
293 Citations2016John R. Teerlink, G. Michael Felker +19 more
Omecamtiv mecarbil dosing guided by pharmacokinetics achieved plasma concentrations associated with improved cardiac function and decreased ventricular diameter, and the frequency of adverse clinical events did not differ between groups.
The LancetDose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study
259 Citations2011John R. Teerlink, Cyril P. Clarke +11 more
First-in-man data show highly dose-dependent augmentation of left ventricular systolic function in response to omecamtiv mecarbil and support potential clinical use of the drug in patients with heart failure.
Journal of the American College of CardiologyAcute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure
219 Citations2016John R. Teerlink, G. Michael Felker +13 more
In patients with AHF, intravenous OM did not meet the primary endpoint of dyspnea improvement, but it was generally well tolerated, it increased systolic ejection time, and it may have improved Dyspnea in the high-dose group.
Nature CommunicationsMechanistic and structural basis for activation of cardiac myosin force production by omecamtiv mecarbil
210 Citations2017Vicente J. Planelles-Herrero, James J. Hartman +3 more
The authors give insights into the mode of action of omecamtiv mecarbil and present the crystal structure of OM bound to bovine cardiac myosin, which shows that OM stabilizes the pre-powerstroke state of myOSin.
JAMA CardiologyEnrollment of Older Patients, Women, and Racial and Ethnic Minorities in Contemporary Heart Failure Clinical Trials
201 Citations2018Ayman Samman Tahhan, Muthiah Vaduganathan +7 more
In contemporary HF trials, older patients and women are consistently underrepresented and race/ethnicity data are reported in less than half of trials; when reported, such data show that enrollment of nonwhite patients increased over time.
Circulation Heart FailureImprovement of Cardiac Function by a Cardiac Myosin Activator in Conscious Dogs With Systolic Heart Failure
168 Citations2010You-Tang Shen, Fady I. Malik +6 more
It is demonstrated that chronic infusion of the cardiac myosin activator, omecamtiv mecarbil, improves LV function in sHF without the limitations of progressive desensitization and increased MVO2.
JACC Heart FailureOmecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction
136 Citations2020John R. Teerlink, Rafael Díaz +10 more
The GALACTIC-HF trial is the first trial examining whether selectively increasing cardiac contractility in patients with HF with reduced ejection fraction will result in improved clinical outcomes and has 90% power to assess a final hazard ratio of approximately 0.80.
Journal of the American College of CardiologyCardiac Calcitropes, Myotropes, and Mitotropes
123 Citations2019Mitchell A. Psotka, Stephen S. Gottlieb +6 more
This review proposes a novel nuanced and holistic framework to categorize pharmacological agents that improve myocardial performance based on 3Myocardial mechanisms: calcitropes, which alter intracellular calcium concentrations; myotrops, which affect the molecular motor and scaffolding; and mitotropes, who influence energetics.
European Journal of Heart FailureWhy has Positive Inotropy Failed in Chronic Heart Failure? Lessons from Prior Inotrope Trials
117 Citations2019Tariq Ahmad, P. Elliott Miller +9 more
The focus of this state‐of‐the‐art review is to revisit prior clinical trials and to understand the causes for their findings, and propose a framework for future trials of positive inotropic agents that maximizes their potential for success.
European Journal of Heart FailureMinimal Clinically Important Difference in Quality of Life Scores for Patients with Heart Failure and Reduced Ejection Fraction
114 Citations2020Javed Butler, Muhammad Shahzeb Khan +7 more
The main objective of this study was to correlate the changes in the KCCQ and Patient Global Assessment in patients with HF with reduced ejection fraction to determine minimal clinically important difference (MCID).
Journal of the Royal Statistical Society Series B (Statistical Methodology)Testing and Confidence Intervals for High Dimensional Proportional Hazards Models
69 Citations2016Ethan X. Fang, Yang Ning +1 more
A unified likelihood ratio inferential framework, including score, Wald and partial likelihood ratio statistics for hypothesis testing, is proposed, motivated by a geometric projection principle.
JACC Heart FailureNatriuretic Peptides as Biomarkers of Treatment Response in Clinical Trials of Heart Failure
56 Citations2018Muthiah Vaduganathan, Brian Claggett +6 more
Therapy-related changes in NPs appeared modestly correlated with longer-term therapeutic effects on hospitalization for HF, but not with effects on all-cause mortality, raising important caveats regarding the use of NPs in phase II trials for decision making regarding phase III trials.
Handbook of experimental pharmacologyDirect Myosin Activation by Omecamtiv Mecarbil for Heart Failure with Reduced Ejection Fraction
30 Citations2017Mitchell A. Psotka, John R. Teerlink
Clinically, the question remains as to whether the possible harm of this minimal troponin release is outweighed by the potential benefits of reduced neurohormonal activation, increased stroke volume and cardiac output, and improved ventricular remodeling in patients treated with omecamtiv mecarbil.
European Journal of Heart FailureRelation Between Therapy-Induced Changes in Natriuretic Peptide Levels and Long-Term Therapeutic Effects on Mortality in Patients With Heart Failure and Reduced Ejection Fraction
10 Citations2019Benjamin S. Wessler, Michael McCauley +3 more
To assess whether natriuretic peptides can be used to reliably predict long‐term therapeutic effect on clinical outcomes for patients with heart failure and reduced ejection fraction, a large number of studies have used NPs to predict these outcomes.